Sean Parsons, CEO of Ellume, the Queensland, Australia-based company that developed the test, which was authorized Dec. 15 by the FDA, told CNBC that it plans to ship the first tests in January. The company said it expects it can produce 20 million tests in the first half of 2021 and even more the second half.
FDA commissioner Stephen Hahn, MD, said the test, called the Ellume COVID-19 Home Test, is a “major milestone” in COVID-19 testing, CNBC reported. Ellume received a $30 million grant from the National Institutes of Health to develop it, and it was found to be 96 percent accurate in identifying symptomatic cases of COVID-19 and 91 percent accurate for asymptomatic cases.
Read the full article here.
More articles on supply chain:
Rural California hospitals struggle with state’s new PPE stockpile mandate
Rare disease patients struggle to find PPE
FDA authorizes first fully at-home COVID-19 test
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
